TL;DR

  • Canary Capital’s Staked INJ ETF secured Nasdaq listing approval under ticker INJC, advancing a product designed to combine Injective exposure with staking rewards.
  • The fund plans to stake at least 90% of its INJ holdings under normal conditions, with BitGo as custodian and a 1.10% sponsor fee.
  • The Injective Foundation indicated plans to buy up to $15 million in seed shares, while listing approval alone does not establish investor demand.

Canary Capital’s Staked INJ ETF has secured approval to list on Nasdaq under the ticker INJC, advancing a product designed to combine direct Injective exposure with staking rewards. In an official Injective post, the network said the ETF targets staking 90% of its institutional INJ holdings. The approval moves a regulated Injective investment vehicle closer to public-market access while preserving staking as a core feature of the structure.

BREAKING: The NASDAQ has officially approved the listing of the first-ever INJ Staked ETF.

The ETF will bring unprecedented exposure to $INJ and will target staking 90% of its institutional holdings in the U.S.

The ticker is INJC. pic.twitter.com/Rb4HhOY29K

— Injective 🥷 (@injective) November 5, 2026

Canary’s INJC ETF Combines Spot Exposure and Staking

The approval was disclosed through a November 3 Form 8-A12B filing registering the fund’s common shares for Nasdaq listing. The product is designed to hold INJ directly, with BitGo serving as custodian, while selected providers handle validator operations. INJC is structured to give brokerage investors exposure to both INJ’s market value and network rewards without requiring them to manage wallets or token delegation themselves, building on Canary’s earlier Staked INJ ETF filing.

Canary Capital’s Staked INJ ETF secured Nasdaq listing approval

Under normal conditions, Canary plans to stake at least 90% of the trust’s INJ holdings. The prospectus sets a 1.10% annual sponsor fee, while staking rewards can vary with network conditions and are not guaranteed. Injective’s 21-day unbonding period also creates a liquidity constraint because tokens leaving staking cannot immediately be transferred. The fund therefore pairs yield generation with operational liquidity requirements, a balance already detailed in Canary’s native staking structure.

The listing approval represents a step from the product’s earlier regulatory path. Canary initially pursued a Cboe listing before moving the fund to Nasdaq under INJC. The Injective Foundation has also indicated plans to purchase up to $15 million in seed shares, although the filing cited in the reference showed no completed subscriptions or institutional inflows. A listing approval establishes the exchange arrangement but does not itself demonstrate investor demand or capital entering the fund, following the earlier Cboe listing proposal.

The structure reflects a broader effort to package proof-of-stake assets inside regulated market products while retaining network economics. Investors would gain access through brokerage accounts rather than holding INJ directly, while staking activity remains handled inside the trust. INJC’s differentiating feature is its attempt to combine regulated exchange access with protocol-level staking rewards, extending Injective’s institutional market infrastructure into an exchange-traded format. The remaining questions center on liquidity, staking returns and investor demand once shares become available to the market.